The Director General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, weekend stated the need for availability of high-quality products that can meet world-class standards.
She made the statement in Lagos during a facility tour of the first In-vitro Diagnostics (IVD) manufacturing site of a health technology company, Colexa Biosensor Limited, a subsidiary of Codix Pharma Limited in Lagos.
The ostensibly excited DG said that as a regulatory body, NAFDAC would continue to monitor the progress of the company and ensure that it remains compliant with good manufacturing practice and other global best practices.
“I will in addition be looking at FDA standards because it is accepted anywhere in the world. The agency will assist in their regulatory compliance as it does with others to provide the needed guidance.
“For an African medical device company, the feat would go a long way in improving the health of nations through access to quality, innovative, technology-enabled healthcare solutions for the prevention, early diagnosis, and management of diseases.”
She advised the company to focus attention on the local market by making quality products that are readily available to Nigerians before venturing into the global market with its 12 locations in Africa, including UAE and UK.
She added that NAFDAC will only allow export of quality products with proven safety and efficacy.
The company said with the introduction of a new plant in Shagamu, things will be a lot easier when it becomes operational in October next year.
Earlier in his speech, the chairman of Colexa Biosensor Limited, Mr. Samson Ogunjimi, stated that the company had provided over 5 million tests of HIV/Syphilis Combo test to the HIV program.
